Test Price
2,800 AED✅ Home Collection Available
FGF14 Gene Spinocerebellar Ataxia Type 27 (Autosomal Dominant) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Next‑Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Interpretation session with a certified genetics specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FGF14 NGS test definitively diagnoses autosomal dominant spinocerebellar ataxia type 27 (SCA27) by sequencing the entire coding region of the FGF14 gene, detecting even rare pathogenic variants. This advanced molecular analysis provides a definitive genetic diagnosis to guide clinical management and family risk assessment.
| Feature | Our NGS Test (ISO 9001:2015) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Diagnostic Precision | Full gene coverage, including deep intronic variants – sensitivity >99.9% | Limited to known exon‑only mutations; may miss rare variants |
| Methodology | Next‑Generation Sequencing (NGS) with bioinformatic validation | Sanger sequencing of select exons |
| Turnaround Time | 3–4 weeks, with possibility of expedited reporting | 4–6 weeks, dependent on reference lab batching |
| Clinical Report | Interpretation by DHA‑licensed genetic specialist, aligned with ACMG guidelines | Standard lab report with basic variant listing |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasise that a genetic diagnosis of SCA27 must always be correlated with a detailed neurological examination and family history. A negative NGS result does not exclude other hereditary ataxias, and a positive variant of uncertain significance calls for expert interdisciplinary review before any clinical action.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
“Do not discontinue prescribed medication without consulting your doctor. Genetic test outcomes inform long‑term management but do not replace ongoing medical supervision.”
Exclusion Criteria & Red Flags
Exclusion Criteria (Do NOT proceed without physician clearance)
- Patient unable/unwilling to give informed consent (mandatory pre‑test genetic counselling)
- Acute neurological decompensation requiring emergency intervention
- Known coagulopathy or severe anemia – home phlebotomy may be deferred
- Minors without legal guardian consent (per UAE legal requirements)
Red Flags – Seek immediate medical attention
- Rapidly progressive ataxia, dysphagia, or diplopia within days
- Loss of consciousness or seizure‑like activity
- Expressions of self‑harm or suicidal ideation
- New‑onset severe headache with vertigo
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of the FGF14 NGS test?
The FGF14 NGS test identifies autosomal dominant mutations causing spinocerebellar ataxia type 27, enabling precise diagnosis and family risk assessment.
2. How is the test performed and what is the turnaround time?
A single blood sample is collected via VIP Mobile Phlebotomy with temperature‑controlled cold‑chain logistics; results are typically available in 3 to 4 weeks.
3. What should I know before undergoing the test?
A mandatory genetic counselling session is required to draw a family pedigree and discuss potential outcomes; no fasting or medication change is needed.
UAE Regulatory & Data Privacy Adherence
This test complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is processed securely within our ISO 9001:2015 certified laboratory.
Clinical & Logistical Metadata
| Test Name | FGF14 Gene Spinocerebellar Ataxia Type 27 (Autosomal Dominant) Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Peripheral Blood |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G11.8 |
| LOINC Code | 55233-1 |
| DHA Facility License & Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians